Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact
Other, Other, Publications

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance

Other, Other, Publications

The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers

Other, Publications, XMT-1522

Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.

September 2019

Other, Publications

An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells

March 2019

Other, Publications

Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)

November 2018

© 2023 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
      • Our Responsibility
      • Who We Are
      • Our Organization
      • Patient Access and Clinical Trial Practices
      • Our Community
      • Our Planet
    • Partnering
  • Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact